511TiP - A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

A.R Hansen,J Strauss,J Chaves,S.A Piha-Paul,H Park,E Garralda,C.J Matheny,J Carver,A Moore,B.A Hug

doi:10.1093/annonc/mdz244.073

511TiP - A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

A.R Hansen, J Strauss + Show 8 more

Open Access

https://doi.org/10.1093/annonc/mdz244.073

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 1	License type: publisher-specific-oa

Affiliation: The University of Texas MD Anderson Cancer Center, University of Washington, Vall d'Hebron Institute of Oncology

#Research Grant #Stock Options + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

511TiP - A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

Full Text